1986
DOI: 10.1016/0161-5890(86)90075-1
|View full text |Cite
|
Sign up to set email alerts
|

Anti-complementary action of polymorphic “solubility forms” of particulate inulin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
48
1
1

Year Published

1987
1987
2019
2019

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 57 publications
(51 citation statements)
references
References 18 publications
1
48
1
1
Order By: Relevance
“…To deplete GPS of alternative complement pathway activity, the serum was incubated with 7-inulin (0.5 mg/ml) at 37 °C for 30 min as described by Cooper & Carter (1986). Inulin was removed by centrifugation in a microfuge (5 min, 4 °C) and the supernatant was stored at -70 °C.…”
Section: Methodsmentioning
confidence: 99%
“…To deplete GPS of alternative complement pathway activity, the serum was incubated with 7-inulin (0.5 mg/ml) at 37 °C for 30 min as described by Cooper & Carter (1986). Inulin was removed by centrifugation in a microfuge (5 min, 4 °C) and the supernatant was stored at -70 °C.…”
Section: Methodsmentioning
confidence: 99%
“…Adjuvancity of inulin was linked to the activation of the complement cascades [50]. Structurally, inulin occurred in various isoforms a, b, g and d. Out of these, g inulin was proven to be a powerful adjuvant in immune activation [18].…”
Section: Natural Polymersmentioning
confidence: 99%
“…This was first recognized with discovery of GI, which was sharply demarcated (Cooper and Steele 1991) and distinct from the poorly characterizable alpha inulin (AI). GI only formed from higher DP fractions isolated by gel exclusion chromatography (Cooper and Carter 1986a), so that the "higher" GI variant did indeed comprise longer polymer chains than AI, and DI had analogous higher DP properties .…”
Section: Introductionmentioning
confidence: 99%
“…Micro-particulate inulin (MPI) was originally developed (Cooper and Carter 1986a) as an anti-cancer therapeutic based on the premise that in vivo alternative pathway complement activation may have anti-tumor effects (Cooper and Masinello 1983;Cooper and Sim 1984;Cooper 1985). The first therapeutic isoform (gamma inulin (GI)) was followed by the more active delta inulin (DI), which is the clinically preferred option .…”
Section: Introductionmentioning
confidence: 99%